resTORbio, Inc. Announces Proposed Public Offering of Common Stock
BofA Merrill Lynch,
The shares are being offered by resTORbio pursuant to a shelf registration statement that was previously filed with, and subsequently declared effective on
- BofA Merrill Lynch, Attention: Prospectus Department, NC1-004-03-43,
200 North College Street, 3rd floor, Charlotte NC28255-0001 (email: email@example.com); or SVB Leerink, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA02110, by telephone at (800) 808-7525, ext. 6132, or by emailing Syndicate@svbleerink.com.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
resTORbio, Inc. is a clinical stage biopharmaceutical company developing innovative medicines that target the biology of aging to prevent or treat age-related diseases. resTORbio’s lead program selectively inhibits TORC1, an evolutionarily conserved pathway that contributes to the decline in function of multiple organ systems, including the immune, cardiovascular and central nervous systems.
This press release contains "forward-looking statements" of resTORbio within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements related to the anticipated public offering of shares. These forward-looking statements include, but are not limited to, those relating to resTORbio’s expectations regarding the completion, timing and size of the public offering, and its expectations with respect to granting the underwriters a 30-day option to purchase additional shares. Any forward-looking statements in this press release are based on management’s current expectations and beliefs of future events, and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties related to completion of the proposed public offering on the anticipated terms, or at all, include, but are not limited to, market conditions and the satisfaction of customary closing conditions related to the proposed public offering. For a discussion of these and other risks and uncertainties, and other important factors, any of which could cause resTORbio’s actual results to differ from those contained in the forward-looking statements, see the section entitled “Risk Factors” in resTORbio’s most recent annual report on Form 10-K filed on